DALLAS, April 05, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALYâ€) today confirmed plans to reveal a fourth research and development initiative for a treatment of a heath issue with a cannabis extract derived from the company’s patented cannabis extraction process. The company currently has ongoing cannabis extract research and development targeting four specific health issues, COPD, Type 2 Diabetes, Cancer Pain Management and one additional health issue KALY plans to announce next week leading up to an online presentation with more detail on each of the treatment developments later this month. The market for Type 2 Diabetes is expected to be a $64 billion market by 2026. The market for COPD treatment is anticipated to reach $14 billion by 2025. The overall pain management treatment market is anticipated to reach $83 billion by 2024.
Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline.
In addition to its pharmaceutical developments,
KALY is generating revenue from its patented cannabis extraction
process delivering proprietary extracts for infusion into
non-pharmaceutical commercial products. KALY announced last
week finalizing its all-new 25 mg CBD Extract formulation for
beverage infusion. KALY’s patented extraction process already
produces a 10 mg CBD formulation for Puration, Inc.’s (PURA) (“PURAâ€) leading EVERx CBD Sports
Water. KALY has also recently announced plans to provide
commercial extraction for Nouveau, Inc. (NOUV) (“NOUVâ€) in conjunction with NOUV’s recently
announced 100-acre hemp farm.
KALY is a health and wellness company set to generate revenue from
its patented cannabis extraction technology through overlapping
go-to-market strategies. In addition to developing
pharmaceutical products internally and through partnerships, KALY
is utilizing is patented cannabis extraction process to develop
numerous wellness products both internally and through
partnerships. The first revenue generating contracts signed in
December of 2018 will be reflected in the company’s upcoming annual
report.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and as such, may involve risks and
uncertainties. These forward looking statements relate to, amongst
other things, current expectation of the business environment in
which the company operates, potential future performance,
projections of future performance and the perceived opportunities
in the market. The company's actual performance, results and
achievements may differ materially from the expressed or implied in
such forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
[email protected]
(214) 210-0459